Title

APOE ε4 Moderates Amyloid-related Memory Decline In Preclinical Alzheimer's Disease

Document Type

Article

Publisher

Elsevier Inc.

Faculty

Faculty of Health, Engineering and Science

School

School of Medical Sciences, Centre of Excellence for Alzheimer's Disease Research And Care

Comments

Originally published as : Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Ames, D., Ellis, K. A., Harrington, K., ... & Maruff, P. (2015). APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiology of aging, 36(3), 1239-1244.Original article available here

Abstract

The apolipoprotein E (APOE) e{open}4 allele and high levels of beta-amyloid (Aβ) are associated with episodic memory decline and risk for Alzheimer's disease. However, there is debate about independent or interactive effects of e{open}4 on Aβ-related memory decline in healthy older adults. Healthy older adults with high Aβ burden (n= 84) enrolled in Australian Imaging, Biomarkers, and Lifestyle Study were included in this study. Cognition was measured using the computerized Cogstate Brief Battery at baseline, 18-, 36-, and 54-month follow-ups. Mini Mental State Examination and Clinical Dementia Rating scales were also administered at baseline and each follow-up timepoint. Relative to Aβ+ e{open}4 noncarriers (n= 36), Aβ+ e{open}4 carriers (n= 48) showed significantly faster decline on memory tasks, which was by convention, moderate in magnitude (d= 0.40-0.47). Aβ positivity coupled with APOE e{open}4 was associated with moderately increased decline in memory over a 54-month assessment period, suggesting that, in the preclinical stages of Alzheimer's disease, the manifestation of memory decline in older adults with high Aβ is exacerbated by the presence of APOE e{open}4.

DOI

10.1016/j.neurobiolaging.2014.12.008

Share

 
COinS